CAMP4 Therapeutics Corporation (CAMP) — Financial statements
Income statement, balance sheet, and cash flow for CAMP4 Therapeutics Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2023 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3↑436.5% | 0.65↑86.3% | 0.35 | 0.00↓100.0% | 296 | |
| Cost of Revenue | 2 | 0.00 | 0.00 | 0.00↓100.0% | 174 | |
| Gross Profit | 2↑185.1% | 0.65↑86.3% | 0.35 | 0.00↓100.0% | 122 | |
| Operating Expenses | ||||||
| R&D Expenses | 38↓1.6% | 39↓4.4% | 41↑16.8% | 35↑22.2% | 28 | |
| General & Administrative Expenses | 17↑16.3% | 15↑28.5% | 12↑13.5% | 10↓80.5% | 52 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 49 | |
| SG&A Expenses | 17↑16.3% | 15↑28.5% | 12↑13.5% | 10↓89.9% | 101 | |
| Other Expenses | -2 | 0.00 | 0.00 | 0.00↓100.0% | 5 | |
| Operating Expenses | 54↑0.3% | 54↑2.9% | 52↑16.1% | 45↓66.6% | 135 | |
| Total Costs & Expenses | 56↑3.4% | 54↑2.9% | 52↑16.1% | 45↓85.4% | 309 | |
| Operating Results | ||||||
| Operating Income | -52↑1.9% | -53↓2.3% | -52↓15.3% | -45↓193.9% | -15 | |
| Depreciation & Amortization | 2↓3.4% | 2↑1.1% | 2↑91.1% | 0.88↓96.1% | 23 | |
| EBITDA | -50↑1.9% | -51↓2.4% | -50↓13.8% | -44↓689.0% | 7 | |
| EBIT | -52↑1.9% | -53↓2.3% | -52↓15.3% | -45↓193.9% | -15 | |
| Interest & Other Income | ||||||
| Net Interest Income | 2↑63.5% | 1↓52.6% | 3↑144.9% | -6↑59.1% | -15 | |
| Interest Income | 2↑63.5% | 1↓52.6% | 3 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 6↓59.1% | 15 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -28↓2285.2% | 1↓49.9% | 3↑219.9% | 0.81↑105.5% | -15 | |
| Income Before Tax | -80↓55.2% | -52↓5.1% | -49↓11.5% | -44↓47.0% | -30 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -80↓55.2% | -52↓5.1% | -49↓11.5% | -44↓41.9% | -31 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -80↓55.2% | -52↓5.1% | -49↓11.5% | -44↓41.9% | -31 | |
| Bottom-Line Net Income | -80↓55.2% | -52↓5.1% | -49↓11.5% | -44↓41.9% | -31 | |
| EPS (Basic) | -2.65↑0.4% | -2.66↑34.6% | -4.07↓352.2% | -0.90↓2.3% | -0.88 | |
| EPS (Diluted) | -2.65↑0.4% | -2.66↑34.6% | -4.07↓352.2% | -0.90↓2.3% | -0.88 | |
| Weighted Average Shares | 30↑55.8% | 20↑60.9% | 12↓66.4% | 36↑2.4% | 35 | |
| Weighted Average Diluted Shares | 30↑55.8% | 20↑60.9% | 12↓66.4% | 36↑2.5% | 35 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.